• 2011-09-09

    GSP药品管理软件,推销一笔1000元(一个连锁店会有多笔,多劳多得) 注意:本任务终端客户仅限于西南地区(四川、重庆、云南、贵洲、西藏),其他地区的酬劳面谈 本软件 是专门为医药零售、零售连锁、医药批发企业开发的专用软件,完全符合GSP规范。亦适合于大、中、小型商业百货零售及批发、连锁企业。本系统达到了标准的现代化物流管理及全面品质管理要求。有助医药商业企业全面实现电子化、自动化、标准化的现代化先进管理模式。它分工明确,对于各个不同部门实现不同的功能,各行其责,便于管理。 本系统集医药商业企业的质量管理、批发、零售、连锁店配货以及进、销、存各项自动化管理功能于一体。系统采用开放式、组件化、平台化设计,可根据个别企业的不同需要增加或修改功能,达到度身定做的目的。信息数据资料库可无限量扩容,完全适合商业企业的现在直至未来的快速发展需求。   产品名称版 本零售价(元)   药房管理系统   (HIS系统)单体店版(单机版)1500   批发店版(网络版)1800   连锁店版(网络版)2000   医院管理系统标准版(网络版)3000   诊所管理系统标准版(网络版)2500 每两个点(电脑)为一笔,一个批发企业会有多个点, 请在销售成功(收到首付款)后,在此提交稿件,每一笔提交一份稿件,获取赏金1000元。

    其它营销
    已完成
  • 2011-09-06

      Enriching Low-Abundance Serum & Plasma Proteins   AWARD: $30,000 USD | DEADLINE: 10/01/11 | ACTIVE SOLVERS: 254 | POSTED: 8/01/11   Source: InnoCentive Challenge ID: 9932714 Type: Theoretical-licensing   Detailed Description & Requirements   Concentrations of proteins in serum and plasma span up to 10 orders of magnitude – e.g. from serum albumin (50 mg/ml) to some cytokines and chemokines (<5 pg/ml)   Protein molecules most useful to researchers exist at levels that are approximately at or below the 10,000 pg/ml range. Detection and quantification of these low-abundance proteins is obscured by the presence of high abundance proteins. Current methods for reducing the concentration of high-abundance proteins are either inefficient, targeted at certain proteins, or introduce bias and other artifacts.   The Seeker is looking to identify novel methods to reliably reduce or eliminate high abundance proteins so that detection of protein analytes present at the 1-10 ng/ml scale or lower may be accurately detected.   The Seeker envisages that a sample preparation techniques may be the most likely route to a solution. However, alternative approaches are also welcomed. The Seeker is highly experienced in sample preparation technologies for reduction of high-abundance proteins & is not interested in simple proposals of commercially available, or published, technologies and techniques.   The Seeker is aware of the following ‘sample enrichment’ technologies for reducing the concentration of high abundance proteins from serum & plasma. The techniques are listed together with their limitations for the Seeker:   Immunoaffinity depletions– depletions are extremely specific to the antigens the antibodies target. Commercially available kits commonly deplete 6-20 high abundance proteins with more than 90% efficiency. Although this enables detection of more low-abundance proteins, the column-based process induces some bias in low-abundance protein populations.   Dye affinity depletions- Depletion of albumin using immobilized dyes such as Cibacron Blue. Limitations are that only albumin is depleted and proteins/peptides that interact with albumin are removed.   Lectin affinity enrichments– low-abundance glycoproteins can be concentrated from serum/plasma using various lectin-binding procedures. Although efficient and specific, lectin enrichment introduces bias in the processed sample and results vary greatly depending on the techniques used.   Peptide/nucleotide affinity reagents–methods based on interactions between abundant proteins and synthetic peptides or nucleotides (i.e. aptamers). Aptamers are fraught with non-specific and low affinity interactions and therefore are not desirable as a method of enrichment.   The Seeker is not interested in a literature review and suggestions of possible techniques. Instead, the seeker requires a novel technology or technique that will dramatically (99.9% efficient) reduce, or eliminate, high abundance (>10 ng/ml) proteins from serum & plasma. Although a ‘universal’ solution is preferred, the Seeker is also interested in solutions that reduce or eliminate only certain classes of protein.   Sample size and source is important – proposed technologies should be amenable to working with 50-1000 µl. Although human plasma and serum are the priority samples, the Seeker would ideally like to employ the successful technology on other mammalian sera and plasma.   A ready-to-use method that offers good ease of use, efficacy and reproducibility is desired. However, the Seeker is willing to develop promising technologies and protocols in partnership with Seekers they judge suitable.   Proposed solutions should fulfill the following Technical Requirements:   1. Sample preparation technologies must:   a. Be novel (not described in literature or commercially available)   b. Be suitable for use with 50-1000 µl volumes   c. Deplete high abundance proteins (>10 ng/ml) or large groups of proteins by 99.9% or more   d. Not deplete or denature the low-abundance proteins. The Seeker is willing to accept some slight modification of low-abundance proteins or some bias in low-abundance proteins following the procedure. However, any bias or modification must be highly reproducible.   2. Prepare sample that are:   a. Depleted of proteins present at concentrations above 10 ng/ml   b. Suitable for use in Mass Spectrometry   3. The method should be adaptable for high throughput applications. Cost must not be prohibitive.   Project Criteria   This is a Theoretical Challenge that requires only a written proposal to be submitted.   The submitted proposal should include the following:   · A thorough description of the proposed method(s) or technologies & their mechanisms of action.   · A listing of any specialized reagents or materials required, including suppliers if known   · An extensive protocol for use of the technology or a roadmap for development of a suitable technology.   · A list of the technologies limitations for the stated application.   · A detailed explanations as to why Solver believes that the proposed solution meets the Requirements listed above. Literature references supporting the approach should be included.   · Solvers who propose a solution similar to the methods listed above should include explanations as to how their proposed solution overcomes their limitations.   · References to practical experience which a Solver may have in the field and an indication of the Solver’s availability to collaborate with the Seeker in developing a solution.   The proposal should not include any personal identifying information (name, username, company, address, phone, email, personal website, resume, etc.)   The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.   To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, they will grant to the Seeker non-exclusive license to practice their solutions.   应征稿件请直接上传到:https://www.innocentive.com

    定制合成
    已结束
  • 2011-09-06

      Seeking a 6/7/5 Annulated Ring System   AWARD: varies | DEADLINE: 10/31/11 | ACTIVE SOLVERS: 30 | POSTED: 8/31/11   Material supply of non-commercial compoundsmatching the shown core structure is desired. The Seeker intends to award multiple Solvers for each of theirqualifying submissions.   In order to submit to this Challenge, youmust allow the Seeker to view the structure of your compound in the StructureSelection stage of the Challenge.   Intellectual Property: In return for the Initial Transfer Fee of$300 or $500 per compound, you are expected to grant the Seeker only anon-exclusive license to test your compound(s) in their in-house assays and/or usethe compound(s) to prepare other compounds for in-house testing.   Source: InnoCentive Challenge ID: 992765   更多要求见附件

    工艺技术
    已完成
写私信
  • 3
  • 交易量
  • 33000
  • 赏金
最近10位访客
  • 药智客

    07-11 15:06
  • 药智客

    07-09 22:48
  • 药智客

    05-28 14:36
  • 药智客

    04-25 18:48
  • 药智客

    04-23 01:00
  • 药智客

    04-21 23:23
  • 药智客

    2020-10-19 08:14
  • 药智客

    2020-10-15 17:56
  • 药智客

    2020-10-15 17:56
  • 药智客

    2020-10-15 17:56